Immediate Impact
62 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
The hallmarks of cancer immune evasion
2024 Standout
Works of Guy Hechmati being referenced
Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective
2017
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Guy Hechmati | 522 | 181 | 197 | 51 | 651 | |
| L.V.A.M. Beex | 540 | 115 | 166 | 32 | 794 | |
| Vassilios Vassiliou | 342 | 387 | 154 | 41 | 667 | |
| Mario R. Velasco | 391 | 123 | 157 | 23 | 621 | |
| Marie Maerevoet | 398 | 87 | 130 | 39 | 787 | |
| Olivier Capitain | 516 | 154 | 259 | 58 | 789 | |
| Scott Carruthers | 495 | 137 | 123 | 25 | 641 | |
| Sérgio D. Simon | 485 | 135 | 168 | 46 | 737 | |
| Dean Ruether | 257 | 203 | 238 | 39 | 690 | |
| Leslie K. Ballas | 183 | 186 | 347 | 78 | 739 | |
| Antonio Santo | 303 | 81 | 345 | 54 | 705 |
All Works
Loading papers...